The clinical success of gefitinib, an inhibitor of EGFR, in a subset of lung cancers with mutations in the TK domain of EGFR, holds a promise for the future of targeted therapy 33, 34, and also leads to the investigation of analogous mutations of HER‐2. Here, ERBB2 is linked to lung carcinoma.